Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 6/20 | 0.44 |
| ▸ | CA2 | P00918 | 6/20 | 0.44 |
| ▸ | CA9 | Q16790 | 5/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | FGF23 | Q9GZV9 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4889869 | 1.00 | CA12 (0.44) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL135614 | 0.82 | CA12 (0.61) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL133729 | 0.82 | CA12 (0.61) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL30251630 | 0.82 | CA12 (0.61) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL133728 | 0.82 | CA12 (0.61) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL11420096 | 0.80 | CA12 (0.59) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL11593458 | 0.80 | CA12 (0.59) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL11337077 | 0.80 | CA12 (0.59) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL11420073 | 0.80 | CA12 (0.59) | CA12CA2CA9SIRT2KDM4E | |
| SCHEMBL8507493 | 0.80 | CA12 (0.59) | CA12CA2CA9SIRT2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | WYETH (US) | 2008-02-07 | — | — | US | disclosed |
| EP-1808429-A3 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-10-31 | — | — | EP | disclosed |
| US-7279600-B2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH (US) | 2007-10-09 | — | — | US | disclosed |
| EP-1808429-A2 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | Wyeth a Corporation of the State of Delaware (US) | 2007-07-18 | — | — | EP | disclosed |
| CN-1784379-A | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH CORP (US) | 2006-06-07 | — | — | CN | disclosed |
| CN-1784379-A | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH CORP (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1620392-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | Wyeth (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | WYETH | 2005-01-27 | — | — | US | disclosed |
| WO-2004099122-A2 | HYDROXY-BIPHENYL-CARBALDEHYDE OXIME DERIVATIVES AND THEIR USE AS ESTROGENIC AGENTS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033049-A1 | Hydroxy-Biphenyl-Carbaldehyde Oxime Derivatives and Their Use As Estrogenic Agents | ESR1, ESR2, ESRRB | CA12 747/4885CA2 641/4885CA9 1033/4885 |
| US-20050020676-A1 | Hydroxy-biphenyl-carbaldehyde oxime derivatives and their use as estrogenic agents | ESR1, ESR2, ESRRB | CA12 747/4885CA2 641/4885CA9 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.